Press Releases
Search
-
10 Nov 2026
Business & Solutions
bioMérieux receives U.S. FDA 510(k) Clearance and IVDR CE marking for VITEK® PRO, its new automated ID/AST instrument to support the fight against antimicrobial resistance
bioMérieux, a world leader in the field of in vitro diagnostics, today announced that VITEK® PRO has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) and the CE marking under IVDR*. This innovative system for microbial identification (ID) and antimicrobial susceptibility testing (AST) supports clinical laboratories in diagnosing infectious diseases and advancing Antimicrobial Stewardship (AMS) efforts. The commercial launch of the solution is planned to begin in the first quarter of 2027.
-
09 Nov 2026
Business & Solutions
bioMérieux receives U.S. FDA 510(k) clearance for the latest versions of the BIOFIRE® FILMARRAY® Gastrointestinal Panels to enhance detection of gastrointestinal pathogens including norovirus
bioMérieux, a world leader in the field of in vitro diagnostics, today announces that the BIOFIRE® FILMARRAY® Gastrointestinal 1.1 (GI1.1) Panel has obtained U.S Food and Drug Administration (FDA) 510(k) clearance and IVDR1 CE marking, and the BIOFIRE® FILMARRAY® Gastrointestinal 1.1 (GI1.1) Panel Mid has received US FDA 510(k) clearance. These PCR* molecular panels test 22 and 11, respectively, of the most common bacteria, viruses, and parasites associated with gastroenteritis, all from one sample, with results available in about one hour.
-
03 Nov 2026
Financial Information
Third-Quarter 2026 Business Review
bioMérieux, a world leader in the field of in vitro diagnostics, today releases its business review for the nine months ending September 30, 2026: Solid performance in Q3 2026 with +8% organic sales growth.
-
22 Oct 2026
Press Release
bioMérieux receives Dual 510(k) Clearance and CLIA Waiver from the FDA for the BIOFIRE® SPOTFIRE® Vaginitis Panel to Advance Women’s Health with Rapid Molecular Diagnostics
bioMérieux's BIOFIRE® SPOTFIRE® Vaginitis (VG) Panel has received Dual 510(k) Clearance and CLIA Waiver* from the U.S. Food and Drug Administration (FDA).
-
19 Oct 2026
Others
WHO Grants Emergency Use Listing for BIOFIRE® Global Fever Special Pathogens Panel, Expanding Access to Differential Diagnostics for the Ebola Response
bioMérieux, a world leader in in vitro diagnostics, announced that the World Health Organization (WHO) has granted Emergency Use Listing (EUL) for the BIOFIRE® Global Fever Special Pathogens Panel, strengthening access to differential diagnostic testing in support of the ongoing Ebola Bundibugyo outbreak affecting the Democratic Republic of the Congo (DRC) and neighboring countries.
-
14 Sep 2026
Financial Information
First-Half 2026 Results
bioMérieux's Q2 2026 sales totaled €981 million, with solid organic growth at +5%, reaching +7% excluding BIOFIRE® respiratory panels. The sales of the GO•28 growth drivers increased by 8.5% organically in Q2 26.
-
13 Sep 2026
Business & Solutions
bioMérieux Highlights Positive Impacts of Rapid, Accurate Diagnostics for Patients and Accepts Industry Awards at ADLM 2026
bioMérieux hosted a press panel and accepted seven 2026 IMV ServiceTrak™ Clinical Laboratory Awards. These awards highlight bioMérieux’s continued commitment to delivering industry-leading diagnostic solutions and exceptional customer support to clinical laboratories.
-
13 Jul 2026
Others
bioMérieux to Showcase Company’s Latest in Diagnostic Innovations at ADLM 2026
bioMérieux announced it will showcase its latest diagnostic solutions and innovations at the 2026 Association for Diagnostics & Laboratory Medicine (ADLM) Annual Conference & Clinical Lab Expo.
-
06 Jul 2026
Business & Solutions
WATCHFIRE™ Solution now available for wastewater monitoring in the United States through BioFire Defense
Salt Lake City, Utah, July 6, 2026 – bioMérieux, a world leader in the field of in vitro diagnostics, announces that the WATCHFIRE™ Solution multiplex PCR test for wastewater monitoring is now available through BioFire Defense, a bioMérieux affiliate company. WATCHFIRE™ offers two panel tests that screen for more than 40 pathogens that cause respiratory and gastrointestinal illnesses with easy near-source testing offering multiple PCR results in about an hour.
-
30 Jun 2026
Business & Solutions
bioMérieux submits 510(k) to U.S. FDA for the latest versions of the BIOFIRE® FILMARRAY® Gastrointestinal Panels to enhance detection of gastrointestinal pathogens
bioMérieux, a world leader in the field of in vitro diagnostics, today announces the submission of the BIOFIRE® FILMARRAY® Gastrointestinal 1.1 (GI1.1) Panel and the BIOFIRE® FILMARRAY® Gastrointestinal 1.1 (GI1.1) Panel Mid to the U.S. Food and Drug Administration (FDA) for 510(k) review. These PCR* molecular panels test 22 and 11, respectively, of the most common bacteria, viruses, and parasites associated with gastroenteritis, all from one sample, with results available in approximately one hour.
-
26 Jun 2026
Business & Solutions
Advancing Women’s Health with Rapid Diagnostics: bioMérieux files a Dual 510(k) /CLIA Waiver application to the FDA for the BIOFIRE® SPOTFIRE® Vaginitis Panel
bioMérieux, a world leader in the field of in vitro diagnostics, has submitted a Dual 510(k)/CLIA Waiver application to the U.S. Food and Drug Administration (FDA) for the BIOFIRE® SPOTFIRE® Vaginitis (VG) Panel. This automated, multiplex PCR test can simultaneously detect the most common causes of vaginitis in 20 minutes, directly at the point of care. With this submission, bioMérieux is intending to expand into women’s and sexual health, bringing rapid and accurate diagnostics closer to patients.
-
18 Jun 2026
bioMérieux introduces Salmonella testing kit on GENE-UP® TYPER to support root cause analysis in the food industry
bioMérieux, a world leader in the field of in vitro diagnostics, today introduces the launch of GENE-UP® TYPER SLM, a new real-time PCR solution supporting rapid root cause analysis by discriminating Salmonella in the food industry environments.
-
23 Apr 2026
Financial Information
First-Quarter 2026 Business Review
bioMérieux, a world leader in the field of in vitro diagnostics, today releases its business review for the three months ended March 31, 2026. Consolidated sales totaled €984 million in the first quarter of 2026.
-
20 Apr 2026
Sepsis
First-of-its-Kind Health Economic Analysis Shows Early Use of Fast Diagnostics in Sepsis Care Could Save Thousands of Lives and Reduce Health System Costs Across G7 Countries
bioMérieux, a world leader in in vitro diagnostics, announces the publication of a multi-country health economic analysis assessing the impact of deploying fast identification and antimicrobial susceptibility testing (ID/AST) early in the care pathway for patients with bloodstream infections at high-risk of sepsis.
-
09 Apr 2026
Pharma Quality Control
bioMérieux Unveils its BIOFIRE® SPOTFIRE® Molecular Testing Solution for the Pharmaceutical Industry, Redefining Rapid Mycoplasma Testing
bioMérieux, a world leader in the field of in vitro diagnostics, announces the launch of BIOFIRE® SPOTFIRE® for pharmaceutical industries, where this innovative molecular testing system is designed to transform quality control. Building on the proven success of the BIOFIRE® FILMARRAY® platform, already adopted by leading global pharmaceutical companies, BIOFIRE® SPOTFIRE® introduces a simple, small and smart approach to mycoplasma detection, helping biopharmaceutical manufacturers strengthen quality control, accelerate decision-making, and protect patients.